Stat News, an award-winning publication for medical news, reported that a Chicago hospital treating severe COVID-19 patients with the antiviral medicine remdesivir is seeing rapid recoveries in fever and respiratory symptoms.
So, is this it? Is the end of the coronavirus crisis simply a matter of Gilead wrapping up the trial, submitting the proper paperwork and scaling up manufacturing? Raffat notes that the study specifically excluded patients on mechanical ventilation. Moreover, an earlier study on Chinese patients wasn’t stopped for efficacy reasons. Unlike the Chicago study, the China trial tested patients given a placebo.
Raffat said there should be cautious optimism around remdesivir, which is administered intravenously.Gilead itself says Phase 3 trial data to be available at the end of April and data from other studies to be available in May. “Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for COVID-19,” the company said.
This drug has been known about for a long time now. It has known side effects as well. That, coupled with some strange call option activity on GILD, seems to suggest that the SEC should be snooping around on this one.
Because he's deep state and wants the economy to crash...
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: YahooNews - 🏆 380. / 59 Read more »
Source: ABC - 🏆 471. / 51 Read more »
Source: TIMEHealth - 🏆 121. / 63 Read more »
Source: ABC - 🏆 471. / 51 Read more »